Literature DB >> 224463

Cyclic AMP receptor triggers nuclear protein phosphorylation in a hormone-dependent mammary tumor cell-free system.

Y S Cho-Chung, D Archibald, T Clair.   

Abstract

Adenosine 3',5'-monophosphate (cyclic AMP) receptor protein of 56,000 daltons increases markedly in mammary tumors induced by 7,12-dimethylbenz[a]anthracene (DMBA) after incubation of tumor slices with cyclic AMP, benzamide, and arginine. Incubation of cytosol from these tumor slices with nuclei from unincubated tumors results in nuclear uptake of the 56,000-dalton cyclic AMP receptor and in phosphorylation of the 76,000-dalton nuclear protein. Binding of the 56,000-dalton receptor and phosphorylation of the 76,000-dalton protein also occur in DMBA tumor nuclei when protein kinase type II of bovine heart is used. The results suggest that cyclic AMP receptor is involved in the nuclear events of a hormone-dependent mammary tumor.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224463     DOI: 10.1126/science.224463

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  4 in total

1.  Modulation of nuclear cyclic AMP-dependent protein kinase in dibutyryl cyclic AMP-treated rat H4IIE hepatoma cells.

Authors:  S P Squinto; R A Jungmann
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

2.  Changes in cyclic AMP-dependent protein kinases during inhibition of mastocytoma cell growth by dibutyryl cyclic AMP.

Authors:  J Evans; J Smart; P Airey; R Ralph
Journal:  Mol Cell Biochem       Date:  1982-04-02       Impact factor: 3.396

3.  Cyclic AMP, nuclear protein kinase and the PY815 cell cycle.

Authors:  M Goulding; R K Ralph
Journal:  Mol Cell Biochem       Date:  1985-05       Impact factor: 3.396

4.  Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer.

Authors:  S Kvinnsland; R Ekanger; S O Døskeland; T Thorsen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.